These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 17242810)
1. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Leitão-Azevedo CL; Guimarães LR; de Abreu MG; Gama CS; Lobato MI; Belmonte-de-Abreu PS Braz J Psychiatry; 2006 Dec; 28(4):301-4. PubMed ID: 17242810 [TBL] [Abstract][Full Text] [Related]
2. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722 [TBL] [Abstract][Full Text] [Related]
3. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825 [TBL] [Abstract][Full Text] [Related]
4. Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E Nord J Psychiatry; 2017 Oct; 71(7):496-502. PubMed ID: 28632422 [TBL] [Abstract][Full Text] [Related]
5. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442 [TBL] [Abstract][Full Text] [Related]
6. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
7. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453 [TBL] [Abstract][Full Text] [Related]
8. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Monteleone P; Martiadis V; Maj M Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J; Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783 [TBL] [Abstract][Full Text] [Related]
10. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Huang TL; Chen JF Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176 [TBL] [Abstract][Full Text] [Related]
11. [Schizophrenia, diabetes mellitus and antipsychotics]. Gury C Encephale; 2004; 30(4):382-91. PubMed ID: 15538314 [TBL] [Abstract][Full Text] [Related]
12. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Attux C; Quintana MI; Chaves AC Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359 [TBL] [Abstract][Full Text] [Related]
13. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186 [TBL] [Abstract][Full Text] [Related]
14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
15. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Melkersson K; Berinder K; Hulting AL Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517 [TBL] [Abstract][Full Text] [Related]
16. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration. Guina J; Roy S; Gupta A; Langleben DD; Elman I Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829 [TBL] [Abstract][Full Text] [Related]
18. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
19. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222 [TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]